8 results about "Glutamatergic" patented technology

The present invention provides a method and device for treating motor dysfunction after spinal cord injury by targeting the lateral hypothalamus (LHA). Specifically, in the present invention, by performing electrical stimulation on glutamatergic neurons in the dorsal part of the caudal LHA, the LHA-PnO-spinal cord circuit is activated to modulate limb motor function in patients with spinal cord injury. The method of the present invention has small side effects and can serve as a potential approach for restoring voluntary motor function in patients with spinal cord injury.

Methods of use, pharmaceutical formulations, and labeled versions of compounds are provided of compounds that penetrate the blood-brain barrier and influence the balance of excitatory versus inhibitory neurotransmission by enantiomer selective modulation of glutamate and GABA metabolism. In some embodiments, a glutamatergic false neurotransmitter is S-2-methylglutamate (S-2MeGlu). In some embodiments a GABAergic false neurotransmitters is R-4 aminopentanomic acid (4APA) or S-4 aminopentanomic acid (S-4APA), with high penetration of the blood brain barrier and low toxicity, therein providing useful pharmacologic or imaging agents.

Artificial expression constructs for modulating gene expression in targeted central nervous system cell types are described. The artificial expression constructs can be used to express synthetic genes or modify gene expression in forebrain glutamatergic neurons.

The invention provides a method and equipment for treating dyskinesia after spinal cord injury by targeting lateral hypothalamus LHA. Specifically, an LHA-PnO-spinal cord loop is activated by performing electrical stimulation on glutamicergic neurons on the back side of the tail of the outer hypothalamus, and the limb movement function of a patient with spinal cord injury is adjusted. The method is small in side effect and can be used as a potential means for the spinal cord injury patient to recover the autonomous movement function.

The application discloses an olfactory training system for activating a motor-olfactory-hippocampal neural network and application, the system comprises a plurality of different odor sources, the odor source is used for alternating olfactory stimulation to stroke patients, so as to improve the cognitive function and / or olfactory function of the patient. The application firstly discloses that the function connection of the motor-olfactory-cognitive brain area is disordered after stroke, the function of the VIP neuron of the motor cortex (MO) around the infarction is inhibited; the VIP neuron of the MO region dominates the GABA neuron of the dorsal peripeduncular area (DP) through an inhibitory pathway, activating the pathway can remove the inhibition of the glutamatergic pyramidal neuron of the DP, enhance the excitatory input to the hippocampal CA3 region, and restore the olfaction and spatial memory. The application proves that the structured olfactory training can activate the loop, and significantly improve the cognitive function of the stroke patient. The application provides a simple and non-invasive stroke rehabilitation strategy.

This pest control composition contains a component (1) and a component (2), wherein: the component (1) is an isoxazoline-based or metadiamide-based compound; and the component (2) is a phenylpyrazole-based compound, a compound acting as a mitochondrial electron transfer system complex III inhibitor, a compound acting as a glutamic-acid-activated chlorine ion channel allosteric modulator, a compound acting as a nicotinic acetylcholine receptor competitive modulator, a compound acting as a chord organ TRPV channel modulator, a compound acting as an acetyl CoA carboxylase inhibitor, a pyrethroid-based compound, benzpyrimoxan, fluhexafon, tyclopyrazoflor, indazapyroxamet, tiapyrachlor, flupyroxystrobin, or cybenzoxasulfyl.

The invention discloses application of human amniotic epithelial stem cells in preparation of drugs for treating depression diseases. The human amniotic epithelial stem cells are harvested after being subjected to pancreatin digestion, centrifugation and resuspension in sequence after being cleaned by mechanically separating an amnion on the inner surface of a discarded in-vitro placenta tissue; and a human amniotic epithelial stem cell regimen for the treatment of depression; the cell is wide in source, free of ethical dispute, low in immunogenicity and free of tumorigenicity, and a novel safe and effective way is provided for depression treatment. The cell preparation can be administered through intravenous injection, intrathecal injection or nasal delivery, and the action mechanism of the cell preparation is that the cell preparation can inhibit excessive activation of glial cells and relieve depression-related neuroinflammatory response, so that the neuron microenvironment is improved. The traditional Chinese medicine composition can effectively promote hippocampal neurogenesis (DCX positive cell increase and the like), regulate the activity of 5-hydroxytryptamine neurons and glutamic acid neurons to restore the steady state of a neural network, and remarkably improve the depression-like behavior of a model mouse.